Kiniksa Pharmaceuticals, which is developing therapies for inflammatory and autoimmune conditions, raised $153 million by offering 8.48 million shares at $18, within the range of $17 to $19. The company offered 21% more shares than originally planned, or $26...read more
Led by digital lending platform GreenSky and global merchant acquirer EVO Payments, eight companies are scheduled to raise a combined $1.3 billion in the week ahead. GreenSky and EVO are joined by three biotechs, a bioprosthetic device company and two small...read more
Kiniksa Pharmaceuticals, a clinical-stage biotech developing treatments for autoinflammatory and autoimmune conditions, announced terms for its IPO on Monday. The Lexington, MA-based company plans to raise $126 million by offering 7 million shares at a...read more
US IPO Weekly Recap: Payment IPOs pay off as 6 deals price ahead of Memorial Day
This week's highlights: 6 IPOs, including 3 biotechs and 2 payment firms, raised $1.4...read more
Kiniksa Pharmaceuticals prices upsized $152 million IPO at $18 midpoint
Kiniksa Pharmaceuticals, which is developing therapies for inflammatory and autoimmune conditions, raised $153 million by offering 8.48 million shares at $18, within the range of $17 to $19. The company offered 21% more shares than originally planned, or $26...read more
US IPO Week Ahead: GreenSky and EVO Payments lead 8-IPO week
Led by digital lending platform GreenSky and global merchant acquirer EVO Payments, eight companies are scheduled to raise a combined $1.3 billion in the week ahead. GreenSky and EVO are joined by three biotechs, a bioprosthetic device company and two small...read more
Inflammatory disease biotech Kiniksa Pharmaceuticals sets terms for $126 million IPO
Kiniksa Pharmaceuticals, a clinical-stage biotech developing treatments for autoinflammatory and autoimmune conditions, announced terms for its IPO on Monday. The Lexington, MA-based company plans to raise $126 million by offering 7 million shares at a...read more